Ocular Therapeutix
Ocular Therapeutix is a Bedford, MA-based biopharmaceutical company that develops ophthalmic therapeutics on its ELUTYX bioresorbable hydrogel platform, currently commercializing DEXTENZA and advancing lead pipeline asset AXPAXLI (an axitinib intravitreal hydrogel) through Phase 3 trials for wet AMD and diabetic retinopathy.
- Company typePublic
- Founded2006
- HeadquartersBedford, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ocular Therapeutix does
Ocular Therapeutix is a Bedford, Massachusetts-based, NASDAQ-listed biopharmaceutical company (OCUL) founded in 2006 that develops and commercializes ophthalmic therapies built on its proprietary ELUTYX bioresorbable hydrogel platform, which enables sustained, localized drug delivery for up to 12 months. Its commercial portfolio consists of DEXTENZA, an FDA-approved dexamethasone ophthalmic insert for post-surgical ocular inflammation and pain, and ReSure Sealant for sealing corneal incisions after cataract surgery; both leverage the same hydrogel technology. The company's lead pipeline asset is AXPAXLI (OTX-TKI), an intravitreal axitinib hydrogel in Phase 3 development for wet age-related macular degeneration, with the SOL-1 superiority trial meeting its primary endpoint at p=0.0006 and an NDA submission planned for Q4 2026 under the 505(b)(2) pathway, plus HELIOS-3 underway in non-proliferative diabetic retinopathy and OTX-TIC (travoprost hydrogel) in Phase 2 for glaucoma. Ocular generates revenue through DEXTENZA product sales distributed via specialty pharmacies to ophthalmic surgeons, with a US-based field sales force and medical science liaison team targeting retina specialists and ophthalmologists in anticipation of an AXPAXLI launch that would target the $15B global branded anti-VEGF market.
Ocular Therapeutix firmographics
Firmographics- Name
- Ocular Therapeutix
- Legal name
- Ocular Therapeutix, Inc.
- Website
- https://ocutx.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Ocular Therapeutix is a Bedford, MA-based biopharmaceutical company that develops ophthalmic therapeutics on its ELUTYX bioresorbable hydrogel platform, currently commercializing DEXTENZA and advancing lead pipeline asset AXPAXLI (an axitinib intravitreal hydrogel) through Phase 3 trials for wet AMD and diabetic retinopathy.
- Ownership category
- akta.pro rank
Ocular Therapeutix industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals
- NAICS
- Ophthalmic Goods Manufacturing (339115), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)
- akta.pro primary industry
- Ophthalmology Pharmaceuticals (HLAIAAAL)
- akta.pro secondary industries
- Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
Keywords
Where Ocular Therapeutix is headquartered
LocationHeadquarters
- HQ city
- Bedford
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Ocular Therapeutix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- DEXTENZA Product Sales: The company generates commercial revenue from sales of DEXTENZA (dexamethasone ophthalmic insert), an FDA-approved product for intracanalicular use. DEXTENZA is a registered trademark of Ocular Therapeutix.
- AXPAXLI (pre-commercial): AXPAXLI is in Phase 3 clinical trials and not yet generating revenue. The company plans to submit an NDA in Q4 2026 for wet AMD. Once approved, this will become a significant revenue driver.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Ocular Therapeutix product offering
Product offeringCore offering
Ocular Therapeutix develops, manufactures, and commercializes ophthalmic therapeutics using its proprietary ELUTYX bioresorbable hydrogel technology for sustained, localized drug delivery. The company sells DEXTENZA (dexamethasone ophthalmic insert) for post-surgical ocular inflammation, ReSure Sealant for corneal incision closure, and is developing the lead investigational product AXPAXLI (axitinib intravitreal hydrogel) for wet AMD and diabetic retinopathy, plus OTX-TIC for glaucoma.
Product overview
Ocular Therapeutix is an integrated biopharmaceutical company focused on retina treatments, operating as a single-platform company built around its proprietary ELUTYX bioresorbable hydrogel technology. The company has one FDA-approved commercial product, DEXTENZA (dexamethasone ophthalmic insert) for post-operative ocular inflammation, and ReSure Sealant for corneal incision sealing. The lead investigational product is AXPAXLI (axitinib intravitreal hydrogel), currently in Phase 3 clinical trials for wet age-related macular degeneration and diabetic retinopathy. Additional pipeline products include OTX-TIC (travoprost intracameral hydrogel) in Phase 2 for glaucoma, both leveraging the ELUTYX platform for sustained drug delivery.
Differentiator
Problem solved
Functional benefit
Brands
- DEXTENZA: FDA-approved dexamethasone ophthalmic insert for intracanalicular use
- AXPAXLI
- ELUTYX
- OTX-TIC
Products and services
- DEXTENZA (dexamethasone ophthalmic insert) FDA-approved dexamethasone ophthalmic insert administered intracanalicularly for the treatment of ocular inflammation and pain following ophthalmic surgery. Sold to ophthalmic surgeons and healthcare providers as a commercial specialty pharmaceutical product.
- ReSure Sealant FDA-approved ophthalmic sealant used to seal corneal incisions following cataract surgery, preventing fluid leakage after intraocular procedures. Sold to cataract surgeons and ophthalmic surgery centers.
- AXPAXLI (OTX-TKI, axitinib intravitreal hydrogel) Investigational axitinib intravitreal hydrogel administered by injection, currently in Phase 3 clinical trials (SOL-1 met primary endpoint p=0.0006; SOL-R ongoing) for wet AMD and Phase 3 trials (HELIOS-2, HELIOS-3) for diabetic retinopathy. Combines a highly potent and selective tyrosine kinase inhibitor with the ELUTYX bioresorbable hydrogel technology for continuous drug delivery for up to 12 months, targeting reduction of injection frequency from every 1-3 months to 1-2 times per year. Intended for retina specialists treating wet AMD and diabetic retinopathy patients.
- OTX-TIC (travoprost intracameral hydrogel) Investigational travoprost intracameral hydrogel administered by intracameral injection for the treatment of glaucoma and ocular hypertension, currently in Phase 2 clinical trials. Designed to provide extended duration of action for long-term reduction and maintenance of intraocular pressure with once-yearly dosing potential. Uses the ELUTYX proprietary hydrogel technology platform. Intended for ophthalmologists treating glaucoma and ocular hypertension patients.
Quantifiable outcome
- 74.1% of AXPAXLI subjects maintained vision at Week 36 vs 55.8% for aflibercept (p=0.0006)
- +4 more outcomes
Companies that use Ocular Therapeutix
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles1 record
Ocular Therapeutix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Ocular Therapeutix partnerships and signals
Strategic signalScale indicators10 records
Recent moves6 records
Expansion highlights6 records
Ocular Therapeutix competitors and assessment
Company assessmentBroad incumbents
- Alcon: Alcon is a global ophthalmic pharmaceutical and medical device leader with a broad portfolio including surgical and pharmaceutical products for retinal disease and glaucoma. Comparable as a major ophthalmic commercial infrastructure competitor, with multiple Ocular Therapeutix executives having Alcon backgrounds.
- Genentech (Roche): Genentech developed and commercializes LUCENTIS (ranibizumab), another major anti-VEGF therapy for wet AMD and diabetic retinopathy. As a foundational retinal disease franchise, LUCENTIS represents the standard of care that AXPAXLI aims to disrupt with its reduced injection frequency.
- Bausch + Lomb: Bausch + Lomb is a diversified ophthalmic company with pharmaceutical, surgical, and consumer vision care products, including treatments for retinal disease and glaucoma. Comparable as a broad incumbent competing across multiple ophthalmic segments, with former Ocular regulatory officer Art Ciociola having held roles at Bausch + Lomb.
- Regeneron Pharmaceuticals: Regeneron commercializes EYLEA (aflibercept), the dominant anti-VEGF therapy for wet AMD that AXPAXLI demonstrated superiority over in SOL-1. Multiple Ocular Therapeutix executives (David Robinson, Steve Meyers, Namrata Saroj) previously held commercial roles at Regeneron, making it a direct comparand for the wet AMD market opportunity.
- IVERIC Bio (Astellas Pharma): IVERIC Bio (acquired by Astellas for $5.9B in 2023) developed IZERVAY for geographic atrophy. Multiple Ocular executives including CEO Pravin Dugel and CFO Todd Anderman previously led IVERIC Bio, providing direct comparability for ophthalmic biopharma strategy and valuation.
Direct peers
- Clearside Biomedical: Clearside Biomedical develops ophthalmic drug delivery technologies including suprachoroidal injection platforms for retinal and choroidal diseases. Comparable as a specialty ophthalmic drug delivery company targeting retinal disease with innovative delivery mechanisms.
- Kodiak Sciences: Kodiak Sciences is developing novel therapeutics for retinal diseases including wet AMD with extended-duration formulations targeting reduced injection burden. Directly comparable as a clinical-stage ophthalmology company pursuing improved anti-VEGF durability.
- EyePoint Pharmaceuticals: EyePoint develops sustained-release ocular drug delivery products including Duravyu for retinal disease, making it the most direct competitor to Ocular Therapeutix's AXPAXLI. Both companies target wet AMD and diabetic retinopathy with extended-duration intravitreal therapies and are currently in active litigation.
Emerging players
- Outlook Therapeutics: Outlook Therapeutics develops ONS-5010/LYTENAVA (bevacizumab), an ophthalmic formulation for wet AMD currently under FDA review. Comparable as an emerging ophthalmic biopharmaceutical company targeting the wet AMD anti-VEGF market.
- Adverum Biotechnologies: Adverum is developing gene therapies for ocular diseases including wet AMD with single-administration treatment potential. Comparable as an emerging retinal disease player with a one-time, long-duration treatment approach that competes on injection burden reduction.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Ocular Therapeutix social profiles
Digital presenceOcular Therapeutix compliance and trust
Trust signalCompliance1 record
Ocular Therapeutix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ocular Therapeutix leadership team
Management profileNumber of profiles
Profiles15 records
Ocular Therapeutix funding detail
Funding detailFunding overview
Funding rounds13 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ocular Therapeutix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ocular Therapeutix
What does Ocular Therapeutix do?
Ocular Therapeutix develops, manufactures, and commercializes ophthalmic therapeutics using its proprietary ELUTYX bioresorbable hydrogel technology for sustained, localized drug delivery. The company sells DEXTENZA (dexamethasone ophthalmic insert) for post-surgical ocular inflammation, ReSure Sealant for corneal incision closure, and is developing the lead investigational product AXPAXLI (axitinib intravitreal hydrogel) for wet AMD and diabetic retinopathy, plus OTX-TIC for glaucoma.
Is Ocular Therapeutix a public or private company?
Ocular Therapeutix is a public company. It is classified as public and is currently operating.
When was Ocular Therapeutix founded?
Ocular Therapeutix was founded in 2006. It employs 251 to 500 people.
Where is Ocular Therapeutix based?
Ocular Therapeutix is headquartered in Bedford, United States, in the North America region.
How does Ocular Therapeutix make money?
Two revenue lines are on record. DEXTENZA Product Sales are the primary driver. The others are AXPAXLI (pre-commercial).
Who are Ocular Therapeutix's main competitors?
Broad incumbents on record are Alcon, Genentech (Roche), Bausch + Lomb, Regeneron Pharmaceuticals and IVERIC Bio (Astellas Pharma). Direct peers are Clearside Biomedical, Kodiak Sciences and EyePoint Pharmaceuticals. Emerging players are Outlook Therapeutics and Adverum Biotechnologies.
Does Ocular Therapeutix have an API?
No public API is recorded for Ocular Therapeutix.
What industry is Ocular Therapeutix in?
Ocular Therapeutix's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts). Its NAICS code is 339115 and its SIC code is 3841.